ALXO — ALX ONCOLOGY HOLDINGS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810182 ·
Last close
$1.94
Market Cap
$261.05M
52W High
$2.41
52W Low
$1.37
ADV30
1,503,370
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,966,000 | -17,927,000 | 178,328,000 | 32,284,000 | 26,981,000 |
| Dec 2025 | 0 | — | -23,021,000 | -22,848,000 | 59,046,000 | 16,373,000 | 33,065,000 |
| Sep 2025 | 0 | — | -22,532,000 | -22,144,000 | 82,723,000 | 23,442,000 | 37,923,000 |
| Jun 2025 | 0 | — | -23,473,000 | -25,949,000 | 95,320,000 | 19,302,000 | 30,905,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,142,000
Investing CF
$82,586,000
Financing CF
$362,000
CapEx
$-212,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-722,817,000
Inventory
—
Receivables
$298,000
ST Investments
$28,417,000
EBIT TTM
$-100,093,000
Pretax Income TTM
$-101,695,000
Interest Exp TTM
$1,602,000
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -100,846,000 | -101,695,000 | 59,046,000 | 33,065,000 | — | -84,142,000 |
| Dec 2024 | 0 | -142,467,000 | -134,850,000 | 147,775,000 | 34,157,000 | — | -121,912,000 |
| Dec 2023 | 0 | -170,278,000 | -160,805,000 | 242,553,000 | 52,841,000 | — | -130,364,000 |
| Dec 2022 | 0 | -127,436,000 | -123,482,000 | 306,489,000 | 43,025,000 | — | -89,223,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.54
Max Pain — expiry 2027-01-15
max pain strike: $1.00 · spot: $1.94 · call oi: 1,423 · put oi: 33
Expected Move to 2027-01-15:
±$1.00
(51.55%) —
implied range
$0.94 –
$2.94
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $260.89M | $3.38 | — |
| CYDY | CytoDyn Inc. | $260.25M | $0.19 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $262.93M | $0.16 | — |
| TRDA | Entrada Therapeutics, Inc. | $263.59M | $6.79 | — |
| FHTX | Foghorn Therapeutics Inc. | $265.97M | $4.53 | — |
News headlines (Yahoo Finance, 1h cache)
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
2026-07-09 17:34 · Yahoo
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
2026-06-30 20:40 · Yahoo
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
2026-06-30 12:00 · Yahoo
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
2026-06-04 03:02 · Yahoo
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
2026-06-01 17:23 · Yahoo
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
2026-06-01 12:00 · Yahoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
2026-05-12 13:40 · Yahoo
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary
2026-05-09 12:30 · Yahoo
ALX Oncology Q1 Earnings Call Highlights
2026-05-08 14:57 · Yahoo
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.